<SEC-DOCUMENT>0001144204-14-011785.txt : 20140226
<SEC-HEADER>0001144204-14-011785.hdr.sgml : 20140226
<ACCEPTANCE-DATETIME>20140226171327
ACCESSION NUMBER:		0001144204-14-011785
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140226
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140226
DATE AS OF CHANGE:		20140226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		14645569

	BUSINESS ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v369866_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">of the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):&nbsp;February
26, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SYNTHETIC BIOLOGICS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center">Nevada</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center">1-12584</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center">13-3808303</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File No.)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">155 Gibbs Street, Suite 412, Rockville,
MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)&nbsp;&nbsp;(Zip
Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code:&nbsp;(734) 332-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.2pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 1.1pt; text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD COLSPAN="4" STYLE="padding-right: 3.3pt; text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; padding-right: 2.2pt; text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 85%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 5.02. &nbsp;Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 26, 2014, Steve H. Kanzer
resigned from the Board of Directors of Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;), and from all other positions with
the Company and its subsidiaries. Mr. Kanzer intends to return his focus to his venture capital and investment banking firms on
a full-time basis, and is not resigning due to any disagreement with the Company on any matter related to the Company&rsquo;s operations,
policies or practices. On February 26, 2014, the Company issued the press release attached hereto as Exhibits 99.1 regarding the
departure described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information included in this Item 5.02
and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
&ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such a filing. The Company undertakes no duty or obligation to update or revise information included in this Report or any of
the Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01.&nbsp; Financial Statements
and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="width: 86%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-indent: 34.1pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Description</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">99.1</TD>
    <TD>Press Release dated February 26, 2014</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-2-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%">SYNTHETIC BIOLOGICS, INC.</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD>Date: February 26, 2014</TD>
    <TD>By: <U>&nbsp;&nbsp;/s/ C. Evan Ballantyne&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;&nbsp;C. Evan Ballantyne</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-3-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="width: 86%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-indent: 34.1pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1pt 0pt 0; text-align: center"><B>Description</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">99.1</TD>
    <TD>Press Release dated February 26, 2014</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-4-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v369866_ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_003.gif" ALT="">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Synthetic Biologics&rsquo; Board of
Directors Accepts Resignation of</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Long-Standing Founder and Board Member</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, February 26, 2014 &ndash;</B>
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens
that cause serious infections and other diseases, announced today that Founder, Board member and subsidiary CEO and President,
Steve H. Kanzer, has resigned from the Company, effective immediately, to return his focus to his venture capital and investment
banking firms on a full-time basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Kanzer founded Synthetic Biologics,
Inc. in 2001 and has served as a member of the Board of Directors since inception, and as Chairman of the Board through February
2010. Mr. Kanzer also served the Company as President from February 2001 until May 2006, Chief Executive Officer from September
2004 until November 2008, Interim Director of Biologic Programs from January 2012 through September 2012, and Licensing Associate
from September 2012 through December 2013. Most recently, Mr. Kanzer served as CEO and President of the Company&rsquo;s majority
owned subsidiary, Synthetic Biomics, Inc., where he successfully led the efforts to in-license the Company&rsquo;s anti-methanogen
and irritable bowel syndrome programs from Cedars-Sinai Medical Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Steve Kanzer&rsquo;s unique sense
for identifying novel technologies and for providing keen strategic insight have been invaluable qualities that helped build the
foundation for Synthetic Biologics,&rdquo; stated Jeffrey Riley, Chief Executive Officer at Synthetic Biologics. &ldquo;As we have
grown over the years into a company leading the pursuit for preventions and treatments targeting specific pathogens that cause
serious infections and other diseases, Steve has remained committed to the best interests of shareholders, employees, clinicians
and patients. We look forward to continuing Steve&rsquo;s legacy of innovation and moving our pipeline of anti-infective candidates
toward the clinic.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Riley concluded, &ldquo;While I and
the entire Board respect Steve&rsquo;s decision, we will miss his distinctive point of view, his extraordinary vision and his astute
guidance. On behalf of the Board and the Company, we thank Steve for his dedication and many years of service, and wish him all
the best in his future endeavors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE MKT: SYN)
is a biotechnology company focused on the development of anti-infective biologic and drug candidates targeting specific pathogens
that cause serious infections and other diseases. The Company is developing an oral treatment to reduce the impact of methane producing
organisms on conditions such as&nbsp;constipation-predominant irritable bowel syndrome (C-IBS), an oral biologic to protect the
gastrointestinal microflora from the effects of IV antibiotics for the prevention of <I>C. diff</I> infection, a series of monoclonal
antibodies for the treatment of Pertussis and <I>Acinetobacter</I> infections, and a biologic targeted at the prevention and treatment
of&nbsp;a root cause of&nbsp;IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting
multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release includes forward-looking
statements on Synthetic Biologics&rsquo; current expectations and projections about future events. In some cases forward-looking
statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot;
&quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot;
and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict and include statements regarding the expected impact of future
trial results and continuing Steve Kanzer&rsquo;s legacy of innovation and moving our pipeline of anti-infective candidates toward
the clinic. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially
from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ
materially from those reflected in Synthetic Biologics&rsquo; forward-looking statements include, among others, future trial results
not meeting our expectations, our ability to successfully innovate and apply our strategic vision and other factors described in
Synthetic Biologics&rsquo; report on Form 10-K for the year ended December 31, 2012 and any other filings with the SEC. The information
in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any
forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required
by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Kris Maly</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President, Corporate Communication</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(734) 332-7800, ext. 22</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">###</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_003.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.gif
M1TE&.#EA1@%!`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y
M!`$`````+`````!%`4``AP``````````,P``9@``F0``S```_P`S```S,P`S
M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9
M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`
M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F
M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_
M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S
M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,
M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`
M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9
M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_
M_\P``,P`,\P`9LP`F<P`S,P`_\PS`,PS,\PS9LPSF<PSS,PS_\QF`,QF,\QF
M9LQFF<QFS,QF_\R9`,R9,\R99LR9F<R9S,R9_\S,`,S,,\S,9LS,F<S,S,S,
M_\S_`,S_,\S_9LS_F<S_S,S___\``/\`,_\`9O\`F?\`S/\`__\S`/\S,_\S
M9O\SF?\SS/\S__]F`/]F,_]F9O]FF?]FS/]F__^9`/^9,_^99O^9F?^9S/^9
M___,`/_,,__,9O_,F?_,S/_,____`/__,___9O__F?__S/___P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"`P$"
M`P$"`P$"`P$"`P$"`P$"`P$"`PC_`+$)'$BPH,&#"!,J7,BPH<.'$"-*G$BQ
MHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRX+6!M`:^%"BMI<V;.'/JW,FS
MI\^?0$/&#$JTJ-&C2),J7<KT9+2#K7Y&=3BUJ=6K(5O%O%8*FM=HUV8>;=5*
MD%FS9+&J]4GV+-JJ'&N2;4OVFB=DG?`B\Y2L*[1K3]FVNG*%A>'"AZ\(@CN8
ML"#"5^`F?/P8\A5LEA5'9J@9LB#,EBMW'BU:=%3*GB4;;&Q:H&C2GF,[;K&X
MM&S8CD-C>RV(A6J"90D;9H&8^.:-<\LFYZKW&-Y@P?22Z@LM<,[!P[.WR&[X
M\\#BV1FV_^+>'3/YRPK'<X]*OKW[[)_!&_X-G+SWWN_S'\:FO__\W?8AA-UP
MVQE6X'#'5417;<HET@HKU[`"32G.(.,,*<B,HE=>>96"356S/%23154A5MB)
MQ*6(HF$#8;<B>@F9J*)`,IJXD(KE(8@CBCSNR,)GO?%(WT#XH7C?83[VV.-B
M2B;IY(\`XOB;>DXJZ=U$=)$U2')DT3+5-=`\\XPU88J)S)G(!$-**Z>8,J)*
M^/F7'8QQ9C=DG<--)5^>"0W(YYYRPF?>>@M1.=R1@0:8Z'NG!5@0GH%>"=&"
MRD5EZ4%BO126A,@\0\HU?(3"QRFGI-3*=DIVYB-Q`R4Y98^LTO_8Y&()[?@9
M=\4UF:MA`0"YXY"N(5D8HBNFB.2QQ/5JZ*Y-(@MED2E*^J&.**)*K;'2BM?*
MEEQ^.%%8845#ZBE\\`%*-&^.!&F"`OEI9[O<;9?MH-P15*R@4)$756:9G<>O
M8X,>".RTW"$ZY[\(QX=P<04NW.B!4+:(ZV%O!3<QNP<-A<V66RZ6B+<&A2B0
MR-AHG&Z+TI`:ZJBECCS0R1CY&*.UP[8;)(ZK^0A7C2EN5ZNU4%8E],TG7BET
ML$(N]!B.WO&<5KLM1@WUU-[*3'55T!:VL[#&045TLO-"Q>5<'Y&E<KG6E>UH
MOKBVN">,-)Y7$*`((B1?V,$2&J.^A3K_"BG>$<D']T%_#S1(>X!#RD)#E'XV
M,$-B&523RJ*>\CA%XZV(MXO1$I0U<5=^CK%PU6)[4,\LT*90G(@E_JO22,J;
MM[67-Z0CBZL+*X!WG&_7PN`'62G>8EH^/1*;IXC*1^T1G8KKD&-+]K:E>V9;
M&,3/%Z2>P+GK;3??Z1%8'H`0`PZ1X+`7#"]Y#15>J'+$@_S1FZVD?(H=H)BB
MO4P5)>GX1*EC6EEPA+NY<6U)!B&@ZWBT0!4-['/$2A'S;M2C]*%H*A!T"(/B
MIQ`O<<D5$\2(_<K%!YA=A&Z@,U[[$->>W]P-4HRY6_?>M;>"9:E297&?^S""
MOAD>*F[>\\@&_[VTDE,LPUPEY(AZ8(4@Q9BO7;H*8,V"]R+^%"8**2J(K7*G
M.2X2T%A@G%7>>$0ZTOV..+\SW^T6USTC`;$X6=G6V%;")A*&,'W:>8]B^M:>
M`V'L.V!TG-S61T.$U&D[P$(,]O*S2(,9*%`#8U@!#1G`'])K/R%AT*5,$KD/
MD4M4]1L(R2BRM"B^*)$'--WWC(6>K^U1(%(<'R49Z$535BEB/+-EZ^270)JQ
M<3)<FPH!K8`EQLW%061C"9M"`8I1*5%Q^0%<?H!G+_5]2'#4X\X@?/B?&B[*
M;]_DDT)Z"$SUN2M6(-$D+^DH#22BJR-F62,3H8>ZZ_W2;E4<8P"]@_\ZU0$3
M:`TLUJY2*;LH`2V,:XQ8K9!E0>+L#I;'HB9RB)><FYQM5";$2'``U;!Q5M*2
M>SN0I!3)IT=VDY)!-$CUHE>I.!7H2.6;"T63PT&/S@F/EI3D'S?2L;1<RA4?
MT1A!-%8_RK$,)AUI2[.D)99!*"F2$=5B5%F`Q5T"DY97=:#2?!E!K6G$:N6\
MX!LE:)!.NL8M9EFG]LQ&%A#B9(3-O.-$%"=1@MUT(3*L3\'RBM)"!@]\?0*G
M-7G8-FY&;(?I(6>?X.?3Z]PO%'+EG%?#5T$!(1"O^?3<+5\Y2U5V]D0/Y%I7
M??-5AK:Q<U%*6M\RFQZ6XJ05RR"76L4S2)O_UDU`M0TI2-TF/L`2+H^H_.C`
MJ/32O.&+L":%7?E:Y=M5<J]]E?)65=)VO(&8XA.@D(8T/J&_C$+EJ?Q+8%0M
MRS3.C#=JHO/L;['Z6>(\\+).^ZHO&SK9W0B@LI,!+^.0B0VYY.03D?A$-.A`
M!XE4+WR#S5EA;2M+`[YGF^7TJTJ;JV!\00K"R+UMA$%Z3O>2-\'OHQ4V0B37
MCD0C$IAH0XJ5T;POBOA1I>/L:NPYQ7&RMCX]\IWK`%I+#Y^VH/BQ%EJ'/.0A
MK9&^#R72(XOSXGW1>#C-2\LL9`&AMV9"$I*(A"0*'+C>&@<M9@%/1P.[8&\V
M^%'Q$F=?U?S7E%:X_[A1\K*<AJ38WX(8A<9!X1,-XAU9&"(6AZ`R-C(UOX.$
MZ!.80#&*]3>I9E4R`%P[Z7?+B]?SSGA5`05=CW?J.:[J4Y>O0PA842I6!SMZ
M5G=,RR$,<8A8K.+5LA@E2DPAB40GFM&36J1_AIO;5>ZVPB!&LYNK.6R]6CB<
M$B:VAM=\9B`F:L\)B1`7#M'J/__Y$->0-4E,P0M%8P(36&+=DP[S.#]=(<D,
M1B>ICVMG]?(YC*$-I'$1BBQF&=FT&[Y"KPS)K%61UB+76/6T5P'H5\>"%2J)
MAB1X46L44_<A'3X/M,<#L;H"DLGF!2.PZE3?-A>'U\<ZTD#IC5`Z4PMVX/_9
MW-+T^&(%'8(+AN`"H&-Q[;"(,KPC_M;-!6(*97RBVT!O0V`T9M;%ACDW:67>
MI399*.G.=C5.'V[4F[YTJCL=:E7/^M29#IRM6YWK"1F$4TN#!15:9!9<$(,8
M#"&&0[S:$*L(=-%!D@E>V-W;N%Z+WO>>$E90^^6`M_8J#"&+$DM$X0P'>B18
MS/?&.[XDK7AYS-T^>&JO`N$E&<;";=%M23#^\:`//46*_J!I3UOP<,?V2ZPC
MU(=H^T.TB(;BN_WYG8O^]KAW""O2#G.WL_KWJW@]1FA1AAU@8QB)[CPF\I[[
MYCN_($1'N^2MO6J:4_L:AA>(QEQA!@A<H`R(Q\3_,`3<LN>;__P$";@8N-#[
MOZ^:VJRH\D02,11(E.$"^-^!*Z+Q<*ITBT0:55.8DWVKH1P:@18908!TD8`"
MN!%^!W.G-WB-\'LO%W_8ARDX1WP[0'Q!<`%"<`$>``%ED`B*X`5>$$);)!!`
M1177%%D?$B2002+W=!%YIE"84X/9QVGBL1NJA27LQ1&SL'OLMW;O1X&L1FV(
M,`LA,G?:=P$=\(1."(40,(53Z`42$30#9'C_-A&3E3D5\1@$"$O'T1O0EB^T
MDH45(6,108;P8G&5MH*$(1*!,`9<0(>K-H&'(`:-T':FEX>.<`BLD(2((`N#
M&!5E\(&(Z('X!P$1P(@T_P!`DK*%S:.##"&)8'B#&=$;<-$;:9@@@U&&*@6*
MP!&'$M,_(W4\+\=^:?=^U+9VK-9V8_!R:D>'8C`&)1,$'>`!N=@!'XA_%S"%
M--!Z#D$8<T&*%"&)$'&)!&&#R8B,7#@XXU%BS'A"HB@Q8:AD+;<111<6@7`(
M,<!^@,>'>1B.@&=Z"`<)(,B+('@!.Q`!.^!]$#`4*'ACC5:-P:(]QMAB4@.)
M"22-&$09]D@C`:F,!ZA5)A&$7:"*JC@&;=>0>3B+M1@B9?"$'G`!&."+%Q`!
M%_`%PO@0BB%3T_@0SJA!P*.&#T&0G:@](TE;O!-/;CA.`1F-^W,19-%Q)8$(
MB/_`!5WPC3<@!CBP?G1HAW7(!4I(?&;@A.N(?R.(<Q!A@R9)%908/C$4DS-(
M$?D((*8X-R]9*S$I8^.1AEH4D!>!?8B0D.R'`VC)!6FIECB@DTE("[20",6'
M?T'0D8%C-"'I$"O9$,;8&%]8E5BB4.,AEIHH,5MI-V))C-]QF*<#(X.IC8;V
M,E`Q"]2FDS+`!=]XF3&``YL9`UWP&7!9!F:@`T-AE[9S(L*QCU21EXPS+,)A
M>*T0`)#Q(R66.2X)FV2H&%USC&()&KH9E:OCFH71$V2!DS@9",AIG(@@&41$
MDVAU$;WY@@!#(D-&G8JI49"13%A"@)61C1*Q4=')2=%5AE3H5Y[F>9[HF9X[
M<317LX_L*3^_03)B(7Q)<8U0!X`>H8#(H9K%I)[^^9]\=S1:IW5/416F":`(
>>IYC@U8599\)^J!*\9X2ZG5:UYXT`:$8VA,!`0`[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
